Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of KH176 in Healthy Male Volunteers
NCT02544217Phase 1Completed
- Sponsor
- Khondrion
- Start
- May 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sonlicromanol in mitochondrial disease, mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS), Leigh syndrome and 1 more (2 arms), sponsored by Khondrion. Primary endpoints: Corrected QT Interval According to Fridericia's Formula at 7 days, Pharmacodynamics of KH176 at Day 7 and 15 more. Started May 2015; status: completed.
02
Drugs
sonlicromanol
03
Conditions
mitochondrial diseasemitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS)Leigh syndromeLeber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT02544217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544217.